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Intravitreal dexamethasone implant (DEX; Ozurdex; Allergan, Inc, Irvine, CA) is an efficacious treatment in the management of macular edema due to diabetes, retinal vein occlusions, and posterior uveitis. Its safety and efficacy has been demonstrated by randomized trials such as GENEVA and MEAD study. [1, 2] Endophthalmitis is a rare but serious ophthalmic complication following injection and intravitreal injection of steroid having 6.92-fold more propensity to cause endophthalmitis when compared with anti-VEGF (0.13% vs 0.019%). There are two hypothesis: first, larger bore of needle used for steroid injection (30 or 32 G for anti-VEGF agents, 27 or 25 G for triamcinolone, and 22 G for the DEX) may a worse final functional prognosis and have a higher risk of postvitrectomy retinal detachment compared with other coagulase-negative Staphylococcus endophthalmitis cases as the organism causes more necrozis and thereby retinal detachment. [3] Silicon oil is known to have antibacterial properties and several studies have shown the benefit of silicon oil in endophthalmitis cases without retinal detachment. [10] Taking in consideration the above facts, filling the eye with silicon oil in our case was a logical approach and the final visual acuity of 6/36 after silicon oil removal was more than we have hoped for.
Conclusion
In conclusion, primary removal of steroid implant and filling the eye with silicon oil appears to be a good approach to any severe endophthalmitis case following Ozurdex ® intravitreal injection, especially if infection with S. lugdunensis. Final visual acuity of 6/36 in our case was better than all other Ozurdex ® endophthalmitis cases from international literature which had a maximum gain in vision of 6/60. [1, 2, 7, 8] facilitate bacterial penetration and second, immunosuppression may cause endophthalmitis with a relatively lower bacterial load. [3] Endophthalmitis rate following DEX range from 0% to 1.3% with 0% in GENEVA study and 1.3% in HURON study. There are few case reports on endophthalmitis following DEX injection.
A PubMed-based search shows report of 11 eyes of endophthalmitis following DEX, the largest case series describing five such cases out of which three were DEX coadministered with bevacizumab. [4] Table 1 illustrates the 11 published cases of endophthalmitis following DEX with isolation of coagulase negative Staphylococcus (CONS) in 5 eyes, Alloiococcus otitidis in one and four eyes with no bacterial growth. Among 5 CONS cases, Species identification was done in 3 cases which showed Staphylococcus epidermidis (n = 2), Staphylococcus lugdunensis (n = 1),while in other 2 cases,species identification was not done. There were no details available in two eyes. Mean duration of presentation was 4.67 days (median: 3; range: 2-15 days). In 6 out of 10 eyes, implant was removed along with vitrectomy. Visual outcome ranged from counting fingers to 6/7.5, but majority had moderate recovery.
Endophthalmitis following intravitreal injections are caused by organisms of conjunctival and skin flora. CONS are the major group of organisms responsible for such infections. Several subspecies, such as S. lugdunensis isolated, show high virulence and rapid destructive properties. The organism form characteristic "Biofilm" around host tissue or prosthetic surfaces, hence has been implicated in systemic infections, such as endocarditis, bone and joint infections, and skin and soft tissue infections. Bacterial biofilms exhibit high levels of resistance and evasion from host immune defenses makes them difficulty to treat; these biolfilms or glycocalyx also interfere with the phagocytosis activity of neutrophils and play a role in bacterial colonization. The present issue of the journal has a publication on S. lugdunensis endophthalmitis following DEX injection highlighting the efficacy of the organism to grow on implants and prosthesis. [11] The recent alerts issued by FDA on increased silicone content in the Ozurdex injection and its temporary withdrawal from the market further raise the question of the facilitation of bacterial growth on silicone and thereby increasing the risk of endophthalmitis. 
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Chiquet et al. [13] Suppurative keratitis and postoperative endophthalmitis are entities described in the eye. [12] Chiquet et al. studied this organism in postcataract surgery endophthalmitis and observed mean duration of presentation to be 7.4 days (median: 7; range: 5-12 days). Among five patients who developed endophthalmitis, four required Pars plana vitrectomy and three (60%) of them developed retinal detachment and ended up in less than ambulatory vision. [13] A case series of three S. lugdnensis endophthalmitis following intravitreal anti-VEGF injections has been described with poor visual outcomes. [14] Summary of S. lugdunensis endophthalmitis characteristics and outcome are briefed in Table 2 . The organism is coagulase negative and is sometimes difficult to differentiate from Staphylococcus aureus; it presents with similar aggressive infections and bacterial endocarditis. It has an aggressive clinical course with retinal detachment in many patients warranting an early vitrectomy and poor visual outcome.
There are no evidence-based guidelines for management of DEX-related endophthalmitis, although they all present with severe vitritis and require aggressive management. There are hypotheses suggesting that implant may act as permanent reservoir of bacteria by protecting them from host immune response; hence, early vitrectomy with implant removal is
